Literature DB >> 3386646

IgG antibody response to polysaccharides in children with recurrent infections.

R S Geha1.   

Abstract

IgG2 subclass deficiency associated with poor antibody response to polysaccharide antigen is a now well-described entity. A newer entity which appears to be at least as common is the recurrent infection with a selective deficiency in the antibody response. At the present time, the antibody response to Haemophilus influenzae type b (Hib) is a good marker for the selective antibody deficiency in these children, as the vast majority of such children made a very poor antibody response to Hib. The data suggest that treatment of these children with prophylactic antibiotics and/or with IV gamma-globulin, depending on the clinical situation, is beneficial. This reinforces the view that the observed abnormality in the antibody response may be causally related to the recurrent infections. Prospective studies of the 10% of 'normal' children who fail to respond to soluble polysaccharide antigen would reveal if there is within this group a higher incidence of recurrent infections. The result of such studies will be important in our understanding of normal as well as abnormal selective antigen-specific antibody deficiencies in children.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3386646

Source DB:  PubMed          Journal:  Monogr Allergy        ISSN: 0077-0760


  3 in total

1.  Herpesvirus serology, aberrant specific immunoglobulin G2 and G3 subclass patterns and Gm allotypes in individuals with low levels of IgG3.

Authors:  A Linde; R Söderström; C I Smith; M Sällberg; H Dahl; R Grubb; J Björkander; L Hammarström
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

2.  Clinical and immunological evaluation of patients with mild IgG1 deficiency.

Authors:  D A Van Kessel; P E Horikx; A J Van Houte; C S De Graaff; H Van Velzen-Blad; G T Rijkers
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

Review 3.  Selective IgG subclass deficiency: quantification and clinical relevance.

Authors:  R Jefferis; D S Kumararatne
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.